How should I manage palmar itching that occurs during methotrexate therapy?

Management of Palmar Itching During Methotrexate Therapy

For palmar itching during methotrexate (MTX) therapy, continue MTX at the current dose while initiating topical moderate-to-high potency corticosteroids (such as mometasone furoate 0.1% or betamethasone valerate 0.1% ointment) to the affected areas, and ensure the patient is taking daily folic acid supplementation (1 mg/day). 1

Initial Assessment and Grading

First, determine the severity of the pruritus:

• Grade 1 (Mild/Localized): Localized itching without significant skin changes
• Grade 2 (Moderate): Intense or widespread itching that is intermittent, with possible skin changes from scratching, limiting instrumental activities of daily living
• Grade 3 (Severe): Intense or widespread constant itching that limits self-care activities or sleep 1

Critical pitfall: Rule out other causes before attributing symptoms solely to MTX. Examine for rash, dry skin (xerosis), contact dermatitis from other exposures, or infection. Review all concurrent medications for potential drug interactions or alternative causes 2.

Treatment Algorithm

For Grade 1 (Mild) Palmar Itching:

• Continue MTX at current dose and monitor for progression 1
• Apply topical moderate/high-potency corticosteroids (mometasone furoate 0.1% or betamethasone valerate 0.1% ointment) to palms twice daily 1
• Alternatively, use topical menthol 0.5% preparations or lotions containing urea or polidocanol for symptomatic relief 1
• Ensure daily folic acid 1 mg is being taken, as this mitigates many MTX-related adverse effects including cutaneous manifestations 3
• Implement gentle skin care with emollients to prevent xerosis 1
• Reassess after 2 weeks: if worsening or no improvement, escalate to Grade 2 management 1

For Grade 2 (Moderate) Palmar Itching:

• Continue MTX at current dose unless symptoms become intolerable 1
• Continue topical corticosteroids as above
• Add oral antihistamines:
  • Non-sedating second-generation (loratadine 10 mg daily) for daytime use
  • First-generation sedating antihistamines (diphenhydramine 25-50 mg or hydroxyzine 25-50 mg) at bedtime if sleep is affected 1
• If antihistamines fail after 2 weeks, add GABA agonists as second-line:
  • Pregabalin 25-150 mg daily, OR
  • Gabapentin 900-3600 mg daily (titrate gradually) 1
• Reassess after 2 weeks: if no improvement, proceed to Grade 3 management 1

For Grade 3 (Severe) or Intolerable Grade 2:

• Interrupt MTX until symptoms resolve to Grade 0-1 1
• Continue topical corticosteroids and oral antihistamines
• Continue GABA agonists (pregabalin or gabapentin) 1
• Consider systemic corticosteroids (prednisone 0.5-1 mg/kg for 7 days) for temporary relief of severe pruritus 1
• Alternative agents for refractory cases include aprepitant (NK-1 receptor antagonist) or doxepin 1
• Reassess after 2 weeks: if no improvement, MTX discontinuation may be necessary 1

Important Considerations

Distinguish from palmar-plantar erythrodysesthesia (PPE): While rare with low-dose oral MTX, PPE has been reported with high-dose intravenous MTX 4, 5, 6, 7. PPE presents with painful erythema, swelling, and potential bullae formation on palms/soles, not just itching. If erythema, pain, or blistering develops, this represents a more serious reaction requiring immediate MTX discontinuation and dermatology consultation 4, 5.

Folic acid supplementation is essential: Daily folic acid 1 mg significantly reduces MTX-related adverse effects including cutaneous manifestations and should be confirmed in all patients 3. This is more effective than once-weekly dosing 3.

Monitor for treatment-related rash: If a papulopustular rash develops concurrently with pruritus, treat the underlying rash as this can decrease pruritic symptoms 1. The pruritus may be secondary to the rash rather than an isolated symptom.

Drug interactions: NSAIDs can be given concurrently with low-dose MTX in patients with normal renal function 3, 8. However, verify renal function and review all medications for potential interactions that could increase MTX toxicity 8.

Avoid abrupt high-dose systemic steroids: While systemic corticosteroids can provide temporary relief, they should be used cautiously and for short durations only, as they are not appropriate for long-term management of MTX-related cutaneous effects 1.